The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Eli Lilly wasn’t one of them. The 10 stocks that made the cut could ...

LLY's orforglipron study results disappoint, shifting investor focus to Novo Nordisk's bid for first FDA-approved oral ...

A federal appeals court revived a lawsuit accusing Sanofi, Eli Lilly, Novo Nordisk, and AstraZeneca of conspiring to restrict ...

The obesity market still only has two clear leaders with approved GLP-1 medications, and frontrunners Eli Lilly and Novo ...

Leaders at Eli Lilly believe heavy investment in the company's manufacturing footprint “sets a high standard that newcomers ...

Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) jumped 3.1% in the afternoon session after the stock rebounded ...

The global autoinjectors market, valued at US$1.08 billion in 2023, stood at US$1.40 billion in 2024 and is projected to advance at a resilient CAGR of 13.6% from 2024 to 2030, culminating in a ...

We read with interest the Correspondence by Zhiqi Yao and colleagues1 published in The Lancet Diabetes & Endocrinology, which ...

More than one in five UK adults tried to access weight-loss medications in the past year alone, according to a survey by the ...

Prices for Indian consumers are expected to come down significantly from the current Rs 17,000-Rs 26,000 monthly.

A new daily pill for obesity, orforglipron, has shown promising results in a major clinical trial, helping patients lose ...

A study found jabs were linked to a 'modestly increased risk' of diabetic retinopathy-a condition caused by damage to blood ...